SDIC Fund Management
Chinese mouse-based drug testing specialist raises $143m
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.
Investors pump $265m into BYD semiconductor unit
BYD Semiconductor, a subsidiary of Chinese vehicle maker BYD, has raised RMB1.9 billion ($265 million) from 14 investors, including Sequoia Capital China.
Chinese medical device start-up receives $100m
Chinese medical instrument provider Peijia Medical has raised a RMB700 million ($100 million) Series C round from a group including Matrix Partners China and Lilly Asia Ventures.
Biotech player Ascentage gains on debut after $53m HK IPO
Ascentage Pharma saw its share price surge 57% during the first day of trading in Hong Kong before closing up 9.9%, following a heavily oversubscribed HK$416.6 million ($53 million) IPO.
China's Biocytogen gets $78m Series D
Chinese contract research organization (CRO) Biocytogen has raised a RMB543 million ($78 million) Series D round led by China Life Insurance and SDIC Venture Capital, a VC arm of the State Development & Investment Corporation (SDIC).
SDIC, Sherpa lead $74m round for China's EpimAb
Shanghai-based biopharmaceutical company EpimAb Biotherapeutics has raised a $74 million Series B round led by SDIC Fund Management and healthcare specialist Sherpa Healthcare Partners.
Chinese chip maker secures $22m Series B
National Chip, a Chinese manufacturer of chips for digital TVs, has raised a RMB150 million ($22 million) Series B round led by China’s State Development & Investment Corporation, with participation from Sinovation Ventures.
Investors commit $234m to Alibaba, SAIC internet car venture
Yunfeng Capital, Shang Qi Capital, and China’s State Development & Investment Corporation (SDIC) have participated in a first round of funding worth more than RMB1.6 billion ($234 million) for Banma Network Technologies, a smart car joint venture established...
China’s Ascentage Pharma files for HK IPO
Ascentage Pharma, a Chinese biopharmaceutical company with several private equity backers, has filed for an IPO in Hong Kong.
VCs commit $22m to China laser developer
SDIC Fund Management, a GP under China’s State Development and Investment Corporation (SDIC), along with the Chinese Academy of Sciences and Suzhou Chengxin Venture Capital, has invested RMB150 million ($22 million) in Everbright Photonics, a maker...
China's Ascentage Pharma gets $150m in Series C funding
Ascentage Pharma, a Chinese biopharmaceutical company primarily focused on treatments for cancer, has raised $150 million in Series C funding.
Chinese state-backed PE fund anchors Foxconn IPO
A private equity fund backed by China’s State Development & Investment Corporation (SDIC) is the largest strategic investor in the RMB27.1 billion ($4.3 billion) Shanghai IPO of a Foxconn Technology Group manufacturing unit.
Advantech, SDIC lead $76m round for China biotech player
Advantech Capital and SDIC Fund Management have led a $76 million Series A round for Chinese biotechnology company KBP Biosciences.
SDIC, AstraZeneca agree China pharma JV
SDIC Fund Management, a GP under China’s State Development & Investment Corporation (SDIC), and AstraZeneca have formed a China-based joint venture that will develop and commercialize new medicines.
China’s Segway & Ninebot raises $100m Series C
China-based electric scooter manufacturer Segway & Ninebot Group - previously known as Ninebot - has raised a $100 million Series C round from the Chinese state-backed SDIC Fund and a fund owned by China Mobile.
SDIC leads $65m round for China's CF PharmTech
SDIC Fund Management, a GP under China’s State Development & Investment Corporation, has led a $65 million Series D round of funding for CF PharmTech, a Chinese manufacturer of inhalers and nasal sprays.
VCs commit $65m to China vaccine developer CanSino Biologics
SDIC Fund Management, a GP under China’s State Development & Investment Corporation, has led a $65 million round of funding for CanSino Biologics, a China-based vaccine developer.